Abdel-Aleem H, Ahmed A, Sabra A M, Zakhari M, Soliman M, Hamed H
Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Egypt.
Int J Gynaecol Obstet. 1996 Dec;55(3):273-9. doi: 10.1016/s0020-7292(96)02770-1.
To assess the value of serum alpha-L-fucosidase as a tumor marker in the diagnosis of ovarian and other female genital tract tumors.
One-hundred fifty-one patients were studied; 101 had different genital tract tumors (malignant ovarian tumors (48), carcinoma of the cervix (13), endometrial carcinoma (6), carcinoma of the vulva (6) and benign tumors (28)). A control group of 50 healthy female patients was included. Serum alpha-L-fucosidase activity was determined in all patients and controls. Serum CA 125 level was also determined in patients with malignant ovarian tumors.
patients with malignant ovarian tumors showed the lowest level of alpha-L-fucosidase activity in comparison to other malignant and benign tumors of the female genital tract and also in comparison to malignant ovarian tumors.
Patients with malignant ovarian tumors showed the lowest level of alpha-L-fucosidase activity in comparison to other malignant and benign tumors of the female genital tract and also in comparison to control group. The majority of ovarian carcinoma patients (90%) had a serum level of < 275 u/ml of alpha-L-fucosidase activity, while more than 90% of the control group and other genital tumors had a serum level of > 275 u/ml. The sensitivity and specificity of serum alpha-L-fucosidase activity in diagnosing epithelial ovarian tumors were 88.5% and 98%, respectively (using a cut-off level of < 275 u/ml). The corresponding figures for CA 125 were 96.2% and 100% (using a cut-off level of > 35 u/ml).
Serum alpha-L-fucosidase enzyme activity can be useful as a tumor marker in diagnosing advanced malignant epithelial ovarian tumors. Its sensitivity and specificity are comparable to CA 125. However, there is a lack of data to support its usefulness in the diagnosis of early stage disease (Stage 1). The cost of doing the test is one-third that of CA 125 and the test can be more widely applied in developing countries.
评估血清α-L-岩藻糖苷酶作为肿瘤标志物在卵巢及其他女性生殖道肿瘤诊断中的价值。
对151例患者进行研究；其中101例患有不同的生殖道肿瘤（恶性卵巢肿瘤（48例）、宫颈癌（13例）、子宫内膜癌（6例）、外阴癌（6例）和良性肿瘤（28例））。纳入50名健康女性患者作为对照组。测定所有患者和对照组的血清α-L-岩藻糖苷酶活性。对患有恶性卵巢肿瘤的患者还测定了血清CA 125水平。
与女性生殖道的其他恶性和良性肿瘤相比，以及与恶性卵巢肿瘤自身相比，患有恶性卵巢肿瘤的患者α-L-岩藻糖苷酶活性水平最低。
与女性生殖道的其他恶性和良性肿瘤相比，以及与对照组相比，患有恶性卵巢肿瘤的患者α-L-岩藻糖苷酶活性水平最低。大多数卵巢癌患者（90%）血清α-L-岩藻糖苷酶活性水平<275 u/ml，而对照组和其他生殖道肿瘤患者中超过90%血清水平>275 u/ml。血清α-L-岩藻糖苷酶活性诊断上皮性卵巢肿瘤的敏感性和特异性分别为88.5%和98%（临界值<275 u/ml）。CA 125的相应数据分别为96.2%和100%（临界值>35 u/ml）。
血清α-L-岩藻糖苷酶活性可作为诊断晚期恶性上皮性卵巢肿瘤的肿瘤标志物。其敏感性和特异性与CA 125相当。然而，缺乏数据支持其在早期疾病（Ⅰ期）诊断中的作用。该检测成本为CA 125的三分之一，可在发展中国家更广泛应用。
